MOUNAINEER-03: Tucatinib in Combination with Trastuzumab and Chemotherapy in Patients With HER2+ CRC

Opinion
Video

Kristen K. Ciombor, MD, discussed the ongoing MOUNTAINEER-03 trial, a global Phase 3 study randomizing patients with untreated HER2-positive colorectal cancer patients to FOLFOX plus tucatinib/trastuzumab versus standard chemotherapy plus a biologic, which she said highlights the importance of upfront molecular testing and could change treatment.

Recent Videos
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.